A detailed history of Rhumbline Advisers transactions in Allovir, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 18,494 shares of ALVR stock, worth $15,165. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,494
Previous 68,999 73.2%
Holding current value
$15,165
Previous $52,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$0.72 - $0.82 $36,363 - $41,414
-50,505 Reduced 73.2%
18,494 $13,000
Q1 2024

May 09, 2024

BUY
$0.64 - $0.78 $3,443 - $4,197
5,381 Added 8.46%
68,999 $52,000
Q4 2023

Feb 08, 2024

SELL
$0.68 - $2.39 $10,843 - $38,110
-15,946 Reduced 20.04%
63,618 $43,000
Q3 2023

Nov 09, 2023

BUY
$2.15 - $3.64 $33,722 - $57,093
15,685 Added 24.55%
79,564 $171,000
Q2 2023

Aug 08, 2023

BUY
$3.17 - $5.82 $49,065 - $90,081
15,478 Added 31.98%
63,879 $217,000
Q1 2023

May 11, 2023

SELL
$3.94 - $7.05 $4,747 - $8,495
-1,205 Reduced 2.43%
48,401 $191,000
Q4 2022

Feb 14, 2023

BUY
$4.7 - $9.98 $8,958 - $19,021
1,906 Added 4.0%
49,606 $254,000
Q3 2022

Nov 10, 2022

BUY
$4.13 - $8.79 $17,643 - $37,550
4,272 Added 9.84%
47,700 $376,000
Q2 2022

Aug 11, 2022

BUY
$3.26 - $7.06 $47,977 - $103,902
14,717 Added 51.26%
43,428 $169,000
Q1 2022

May 12, 2022

BUY
$6.75 - $13.52 $6,945 - $13,912
1,029 Added 3.72%
28,711 $194,000
Q4 2021

Feb 10, 2022

SELL
$12.94 - $25.99 $6,806 - $13,670
-526 Reduced 1.86%
27,682 $358,000
Q3 2021

Nov 12, 2021

BUY
$16.97 - $25.06 $22,247 - $32,853
1,311 Added 4.87%
28,208 $707,000
Q2 2021

Aug 05, 2021

SELL
$19.44 - $25.06 $38,199 - $49,242
-1,965 Reduced 6.81%
26,897 $531,000
Q1 2021

May 06, 2021

BUY
$20.81 - $45.5 $186,457 - $407,680
8,960 Added 45.02%
28,862 $675,000
Q4 2020

Feb 10, 2021

BUY
$23.94 - $46.81 $92,384 - $180,639
3,859 Added 24.05%
19,902 $765,000
Q3 2020

Nov 12, 2020

BUY
$21.05 - $42.7 $337,705 - $685,036
16,043 New
16,043 $441,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $76.3M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.